Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes
Executive Summary
Emerging Company Profile: Pionyr Immunotherapeutics exec who once led early development for Merck's PD-1 inhibitor Keytruda explains the San Francisco start-up's approach to rebalancing the tumor's microenvironment in order to improve outcomes.
You may also be interested in...
Gilead Wagers $275m On Pionyr’s Myeloid Tuners
Deal snapshot: Pionyr’s top two candidates are preclinical, but Gilead buys near 50% stake in the hope that myeloid tuners will work in combination with anti-PD-L1 agents in solid tumors.
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Need a specific report? 1000+ reports available
Buy Reports